This is a mobile optimized page that loads fast, if you want to load the real page, click this text.

PER - Percheron Therapeutics

Jump to new
ANP is my pick for the November tipping comp.
They possibly have the most promising treatment for Duchennes Muscular Dystrophy, a truly horrific disease for which there is currently no effective therapy. ANP has conducted a successful Phase 2 trial.
In the pipeline ANP has other products to tackle MS, Acromegaly and cancer.
A cap raise has stalled the rise that positive news for Europe was about to bring.
 
ANP is one of my picks in the 2022 tipping comp. Exciting new(ish) technology that provides hope for a wide range of diseases using genetic manipulation. Many of the diseases they are working on currently have little or no effective treatments. If they succeed in just one their MC will be many multiples of where it is now.
 
On January 4th, 2024, Antisense Therapeutics Limited (ANP) changed its name and ASX code to Percheron Therapeutics Limited (PER).
 
Percheron is my March Competition selection, this company is fully funded through to various end stage trials due in the second half of 2024. It is important to note their board is packed with experienced members able to steer the good work of researchers in this worthwhile cause with the hope will help trial participants and ultimately shareholders.
 
PER is my wildest guess entry for Jan 25 tipping.
After spending a few minutes reading the stock announcement, it was a blindfolded guess entry.
Directors spent their own money even after a failed study - why ?

Too optimistic, or is the inferred impact too little to overshadow the big picture?


https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02899707-3A659122 - A director bought 1.67 million SHARES
https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02899032-3A658994 - another director bought 1.5 m shares
Trading Halt https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02894972-3A658223'
This is the announcement on 18 Dec 24, when the CEO was disappointed with the test result but put his trust in reinvesting however

https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02896214-3A658427

cdn-api.markitdigital.com

 
Another purchase by a director on 31 Dec. interesting if they are supporting my tip for Jan
 
You must log in or register to reply here.
Menu
Log in
Register
Cookies are required to use this site. You must accept them to continue using the site. Learn more...